TXMD
TherapeuticsMDBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The post-earnings update modestly improved the near-term picture: Q1 license revenue rose to $724 thousand from $393 thousand, continuing-operations net income turned positive at $103 thousand, and cash increased to $8.4 million from $7.5 million at year-end, which supports a monitoring thesis that the royalty model can cover a leaner cost base for now [#8-K-2026-05-12] [#10-Q-2026-05-12].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
License revenue is concentrated around the Mayne relationship, so weaker product sales, royalty disputes, or offsets could impair the only meaningful operating cash source [#8-K-2026-05-12] [#10-Q-2026-05-12].
Momentum
86
Value
53
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.05 · Bull $2.60 · Bear $1.20
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Why
Momentum86 · Δ7d -
Value53 · Δ7d +0.1
Sentiment46 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
86
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
53
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
46
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 85.8 / Value 53.3 / Sentiment 45.5
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$24.54M
Beta
0.51
Shares Out
11.57M
P/E (TTM)
288.5
P/S (TTM)
7.45
P/FCF (TTM)
10.07
Rev YoY
+43.3%
EPS YoY
+108.8%
Gross Margin
+31.5%
Op Margin
-98.2%
Net Debt
-$5.06M
Current Ratio
2.93
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology